19 research outputs found
Scientific Abstract to Full Paper: Publication Rate over a 3-Year Period in a Malaysian Clinical Research Conference
No full textBackground: The publication rates of abstracts after they were presented at the National Conference for Clinical Research (NCCR), a scientific conference held in Malaysia, was determined to gauge the scientific value of the conference, whilst providing comparative information with other scientific conferences. Methods: All the abstracts that were presented at the NCCR from 2014 to 2016 were analysed. Keywords from the abstract title, along with the first, second, and last author’s name, were searched via PubMed, Google Scholar, and Scopus to determine publication status. Results: A total of 320 abstracts were analysed. Of those, 57 abstracts (17.8%) were published. Almost 70% of published abstracts appeared in open access journals that charge article processing fees. Early publications (≤18 months from the conference date) had higher median journal impact factors compared to later publications. Approximately 42% of the published abstracts had collaborations with the Institute for Clinical Research (ICR) or Clinical Research Centres (CRCs). An increasing number of authors in an abstract and having the first author from a research centre, reduced and increased the odds of publication, respectively. Conclusions: The NCCR publication rate is lower compared to the reported average in other scientific conferences abroad. More encouragement and support to publish should be provided to the presenting authors. Clinicians should also be encouraged to collaborate with research centres such as those from the ICR or CRCs to boost publication likelihoods
A Safe Home Quarantine Digital Solution for COVID-19: A Proof-of-Concept Study
No full textIntroduction: Malaysia implemented home quarantine for COVID-19 patients with mild symptoms in response to the upsurge in the daily confirmed cases. Nevertheless, monitoring of vital signs while in quarantine is important. The aims were to assess the functionality and usability of a newly developed home quarantine digital solution (CODIQ-My) for remote monitoring. Methodology: COVID-19 patients with mild clinical symptoms designated to a low-risk quarantine centre were selected and instructed on CODIQ-My Solution which incorporates 3 elements; i. patient mobile application ii. vital signs biosensor iii. centralized monitoring dashboard Twice daily, the patients reported their symptoms as well as their vital signs - body temperature (T), oxygen saturation (SpO2), and heart rate (HR) using the biosensor and mobile application. Individual patient information was then captured in the dashboard. The consolidated data was analyzed to test system performance and functionality. Results: A total of 31 mild COVID-19 patients from MAEPS were recruited into the study between 21 May and 23 June 2021. During the study period, 193 (98.0%) check-in attempts were performed and recorded 455 (78.6%) vital readings were successfully and 3 (9.7%) patients failed to use the CODIQ-My due to technical delay. A total of 472 alerts were triggered, with 207 (43.9%) for device communication failure, 149 (31.6%) for user photo mismatch, 64 (13.6%) for quarantine breach, 32 (6.8%) for abnormal vital signs, and 20 (4.2%) for biosensor failure. Discussion/Conclusion: Emerging technology such as validated biosensors and artificial intelligence algorithms can enhance patient management in a pandemic. Our study indicated that the CODIQ-My solution is a secure and robust system with the ability to detect warning signs in quarantine patients. Health care providers can monitor patients remotely and provide fast and targeted treatment plans apart from monitoring the physical movements of these patients with its geofencing ability. Further studies are planned to enhance the biosensor performance by incorporating an infrared temperature sensor and improvising the existing photoplethysmography (PPG) sensor. [Disclaimer: Abstract text might vary slightly from what is displayed in the e-poster]This poster was submitted to the 14th National Conference for Clinical Research (NCCR) on August 18-20 2021. https://nccrconference.com.my
Surge Capacity Dynamics at a COVID-19 Designated Hospital in Malaysia
No full textNCCR 2020: Conference Of Very Important Disease (COVID-19) | 24 - 26 August 2020
Young Investigator Awards Presentatio
Scientific Abstract to Full Paper: Publication Rate over a 3-Year Period in a Malaysian Clinical Research Conference
No full textAbstract: Background: The publication rates of abstracts after they were presented at the National
Conference for Clinical Research (NCCR), a scientific conference held in Malaysia, was determined to
gauge the scientific value of the conference, whilst providing comparative information with other
scientific conferences. Methods: All the abstracts that were presented at the NCCR from 2014 to
2016 were analysed. Keywords from the abstract title, along with the first, second, and last author’s
name, were searched via PubMed, Google Scholar, and Scopus to determine publication status.
Results: A total of 320 abstracts were analysed. Of those, 57 abstracts (17.8%) were published. Almost
70% of published abstracts appeared in open access journals that charge article processing fees.
Early publications (18 months from the conference date) had higher median journal impact factors
compared to later publications. Approximately 42% of the published abstracts had collaborations with
the Institute for Clinical Research (ICR) or Clinical Research Centres (CRCs). An increasing number
of authors in an abstract and having the first author from a research centre, reduced and increased the
odds of publication, respectively. Conclusions: The NCCR publication rate is lower compared to the
reported average in other scientific conferences abroad. More encouragement and support to publish
should be provided to the presenting authors. Clinicians should also be encouraged to collaborate
with research centres such as those from the ICR or CRCs to boost publication likelihoods
Clinical characteristics and risk factors for severe COVID-19 infections in Malaysia: A nationwide observational study
No full textBackground COVID-19 emerged as a major public health outbreak in late 2019. Malaysia reported its first imported case on 25th January 2020, and adopted a policy of extensive contact tracing and hospitalising of all cases. We describe the clinical characteristics of COVID-19 cases nationwide and determine the risk factors associated with disease severity.
Method Clinical records of all RT-PCR confirmed COVID-19 cases aged ≥12 years admitted to 18 designated hospitals in Malaysia between 1st February and 30th May 2020 with complete outcomes were retrieved. Epidemiological history, co-morbidities, clinical features, investigations, management and complications were captured using REDCap database. Variables were compared between mild and severe diseases. Univariate and multivariate regression were used to identify determinants for disease severity.
Findings The sample comprised of 5889 cases (median age 34 years, male 71.7%). Majority were mild (92%), and 3.3% required intensive care, with 80% admitted within the first five days. Older age (≥51 years), underlying chronic kidney disease and chronic pulmonary disease, fever, cough, diarrhoea, breathlessness, tachypnoea, abnormal chest radiographs and high serum CRP (≥5 mg/dL) on admission were significant determinants for severity (p<0.05). The case fatality rate was 1.2%, and the three commonest complications were liver injuries (6.7%), kidney injuries (4%), and acute respiratory distress syndrome (2.3%).
Interpretations Lower case fatality rate was possibly contributed by young cases with mild diseases and early hospitalisation. Abnormal chest radiographic findings in elderly with tachypnoea require close monitoring in the first five days to detect early deterioration
Clinical Characteristics and Risk Factors for Severe COVID-19 infections in Malaysia
No full textIntroduction COVID-19 started as a major public health outbreak in late 2019.1 Malaysia reported its first imported case on 25 January 2020, and adopted a policy of extensive contact tracing and hospitalizing of all patients, regardless of severity.2 We aim to describe clinical characteristics of COVID-19 patients nationwide and determine the risk factors associated with severe COVID-19 disease.
Methodology Clinical records of all RT-PCR confirmed COVID-19 patients admitted to 18 designated hospitals in Malaysia between 1 February and 30 April 2020 with complete outcomes were retrieved. Variables were compared among patients classified as mild (Stage IIII) and severe (Stage IV-V) diseases.3,4 Univariate and multivariate regression analyses were used to identify determinants for disease severity.
Results Our cohort comprised of 5889 cases (median age 34 years, male 71·7%). The majority were mild (92%), only 3·3% required intensive care with 80% admitted within the first 5 days. Older age (>51years), fever, cough, diarrhoea, breathlessness, tachypnoea, high serum CRP (≥5mg/dL) and abnormal chest radiographs on admission were significant determinants for disease severity (p >0·05). The case fatality rate was 1·2% and the three commonest complications were liver injuries (6·7%), kidney injuries (4%), and acute respiratory distress syndrome (2·3%)(Table 1).
Discussion / Conclusion Lower case fatality rate was contributed by young and mild presenting COVID-19 patients.5 Abnormal chest radiographic findings in symptomatic elderly with tachypnoea require close monitoring in first 5 days to detect early deterioration. Early hospitalisation allows risk stratification and monitoring of patients for timely interventions
Clinical staging and criteria for hospital admission.
No full textClinical staging and criteria for hospital admission.</p
Health-related quality of life findings for study participants.
No full textHealth-related quality of life findings for study participants.</p
Distribution of symptoms at 3 months among study participants with post COVID-19 condition (n = 1,510).
No full textDistribution of symptoms at 3 months among study participants with post COVID-19 condition (n = 1,510).</p
Study participants at data collection points throughout the study duration.
No full textStudy participants at data collection points throughout the study duration.</p
